<sentences><s id="0">Association of a <e id="UNIPROT:O00748:T116:PRGE">carboxylesterase 1</e> polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.</s>
<s id="1"><e id="UNIPROT:O00748:T116:PRGE">Carboxylesterase 1</e> is the enzyme involved in methylphenidate (MPH) metabolism.</s> <s id="2">The aim of this study was to evaluate the association between a -75 T&gt;G polymorphism and appetite reduction in children with attention-deficit/hyperactivity disorder (ADHD).</s> <s id="3">A sample of 213 children with ADHD was investigated.</s> <s id="4">The primary outcome was appetite reduction measured by the Barkley Stimulant Side Effect Rating Scale applied at baseline, at 1 and 3 months of treatment.</s> <s id="5">MPH doses were augmented until no further clinical improvement or significant adverse events occurred.</s> <s id="6">The G allele presented a trend for association with appetite reduction scores (P=0.05).</s> <s id="7">A significant interaction between the G allele and treatment over time for appetite reduction scores was also observed (P=0.03).</s> <s id="8">The G allele carriers presented a higher risk for appetite reduction worsening when compared with T allele homozygotes (odds ratio=3.47, P=0.01).</s> <s id="9">The present results suggest an influence of <e id="UNIPROT:O00748:T116:PRGE">carboxylesterase 1</e> -75 T&gt;G polymorphism on the worsening of appetite reduction with MPH treatment in youths with ADHD.The Pharmacogenomics Journal advance online publication, 12 June 2012; doi:10.1038/tpj.2012.25.</s></sentences>